JAGX Earnings

JAGX reported its earnings on 2025-11-12, showcasing a revenue of 0.00 against an estimate of 0.00, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0 by 0% . The stock experienced a 0.57% price change on the earnings day and a 3.74% change over the next five days, reflecting market reactions to the results.

Following JAGX's earnings announcement on 2025-11-12, the stock price moved by 0.57% on the day of the release. Over the subsequent five days, it saw a 3.74% change. Historically, JAGX's stock price tends to shift by an average of +23.72% in the 10 days leading up to earnings and -26.76% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate JAGX’s annual revenue to reach 4.00M, while the EPS is projected at -4.00. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates No Change by 0% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between JAGX's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved No Change by 0% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, JAGX's stock price typically moves by +23.72% in the 10 days before its earnings and -26.76% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -4.00 and revenue of 4.00M.

The earnings call presents a mixed picture. Positive aspects include strategic partnerships, orphan drug designation, and slight revenue growth. However, financial performance shows ongoing losses, and there are significant risks related to market acceptance, competition, and regulatory hurdles. The Q&A section did not provide additional insights to alter these perceptions. The absence of a shareholder return plan discussion and mixed financial metrics suggest a neutral impact on stock price.